Anti-major histocompatibility complex antibody responses in macaques via intradermal DNA immunizations

Vaccine

Volumn 18, Issue 27, 2000, Pages 3152-3165

  Dela Cruz, Charles S ^a   MacDonald, Kelly S ^a,b   Barber, Brian H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Antibodies; DNA vaccine; Macaques; MHC

Indexed keywords

DNA VACCINE; HLA ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLASMID DNA;

ALLOIMMUNIZATION; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; IMMUNIZATION; MACACA; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL;

EID: 0034662387     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00086-4     Document Type: Article

References (63)

1. Fauci A.S. The AIDS epidemic-considerations for the 21st century. N. Engl. J. Med. 341:1999;1046-1050.
2. Zolla-Pazner S., Gomy M.K., Nyambi P.N. The implications of antigenic diversity for vaccine development. Immunol. Lett. 66:1999;159-164.
3. Price D.A., Meier U.C., Klenerman P., et al. The influence of antigenic variation on cytotoxic T lymphocyte responses in HIV-1 infection. J. Mol. Med. 76:1998;699-708.
4. Tremblay M.J., Fortin J.-F., Cantin R. The acquisition of host-encoded proteins by nascent HIV-1. Immunol. Today. 19:1998;346-351.
5. Arthur L.O., Bess J.W. Jr, Sowder R.C. 2nd, et al. Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines. Science. 258:1992;1935-1938.
6. Schols D., Pauwels R., Desmyter J., De Clercq E. Presence of class II histocompatibility DR proteins on the envelope of human immunodeficiency virus demonstrated by FACS analysis. Virology. 189:1992;374-376.
7. Gelderblom H., Reupke H., Winkel T., et al. MHC-antigens: Constituents of the envelopes of human and simian immuodeficiency viruses. Z. Naturforsch. 42:1987;1328-1334.
8. Murphey-Corb M., Martin L.N., Davison-Fairburn B., et al. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science. 246:1989;1293-1297.
9. Desrosiers R.C., Wyand M.S., Kodama T., et al. Vaccine protection against simian immunodeficiency virus infection. Proc. Natl. Acad. Sci. USA. 86:1989;6353-6357.
10. Stott E.J. Anti-cell antibody in macaques. Nature. 353:1991;393.
11. Langlois A.J., Weinhold K.J., Matthews T.J., et al. Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. AIDS Res. Hum. Retroviruses. 8:1992;1641-1652.
12. Chan W.L., Rodgers A., Hancock R.D., et al. Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response. J. Exp. Med. 176:1992;1203-1207.
13. Gardner M., Rosenthal A., Jennings M., et al. Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res. Hum. Retroviruses. 11:1995;843-854.
14. Chan W.L., Rodgers A., Grief C., et al. Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H. AIDS. 9:1995;223-228.
15. Arthur L.O., Bess J.W. Jr, Urban R.G., et al. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J. Virol. 69:1995;3117-3124.
16. Dela Cruz C., Chamberlain J., MacDonald K., Barber B. Xenogeneic and allogeneic anti-MHC immune responses induced by plasmid DNA immunization. Vaccine. 17:1999;2479-2492.
17. Barnstable C.J., Bodmer J.F., Brown G., et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens - New tools for genetic studies. Cell. 14:1978;9.
18. Watanabe N., McAdam S.N., Boyson J.E., et al. A simian immunodeficiency virus envelope V3 cytotoxic T-lymphocyte epitope in rhesus monkeys and its restricting major histocompatibility complex class I molecule Mamu-A*02. J. Virol. 68:1994;6690-6696.
19. Terasaki P.I., Kreisler M., Mickey R.M. Presensitization and kidney transplant failures. Postgrad. Med. J. 47:1971;89-100.
20. Pei R., Wang G., Tarsitani C., et al. Simultaneous HLA class I and class II antibodies screening with flow cytometry. Hum. Immunol. 59:1998;313-322.
21. Heise E.R., Cook D.J., Schepart B.S., et al. The major histocompatibility complex of primates. Genetica. 73:1987;53-68.
22. Keever C.A., Heise E.R. The major histocompatibility complex of the cynomolgus monkey. II. Polymorphism at three serologically defined loci and correlation of haplotypes with stimulation in MLC and skin graft survival. Hum. Immunol. 12:1985;143-164.
23. Manning C.H., Heise E.R. Biochemical analysis of class I and class II MHC antigens in cynomolgus macaques by one-dimensional isoelectric focusing. Tissue Antigens. 37:1991;56-65.
24. Watkins D., Kannagi M., Stone M., Letvin N. Major histocompatibility complex class I molecules of nonhuman primates. Eur. J. Immunol. 18:1988;1425-1432.
25. Schepart B.S., Buck D.A., Manning C.H., et al. Restriction fragment polymorphism of the cynomolgus monkey major histocompatibility complex. Exp. Clin. Immunogenet. 7:1990;109-122.
26. Boyson J.E., Shufflebotham C., Cadavid L.F., et al. The MHC class I genes of the rhesus macaques: different evolutionary histories of MHC class I and II genes in primates. J. Immunol. 156:1996;4656-4665.
27. Manning C.H., Heise E.R. Establishment and characterization of Macaca fascicularis lymphoblastoid cel lines. J. Med. Primatol. 21:1992;15-23.
28. Rowland-Jones S., Tan R., McMichael A. Role of cellular immunity in protection against HIV infection. Adv. Immunol. 65:1997;277-346.
29. Kalams S.A., Walker B.D. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188:1998;2199-2204.
30. Roger M. Influence of host genes on HIV-1 disease progression. FASEB J. 12:1998;625-632.
31. Le Grand R., Vaslin B., Vogt G., et al. AIDS vaccine developments. Nature. 355:1992;684.
32. Cranage M.P., Ashworth L.A.E., Greenaway P.J., et al. AIDS vaccine developments. Nature. 355:1992;685.
33. Shearer G.M., Pinto L.A., Clerici M. Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS. Immunol. Today. 20:1999;66-71.
34. Kiprov D.D., Sheppard H.W., Hanson C.V. Alloimmunization to prevent AIDS? Science. 263:1994;737-738.
35. Mittleman B.B., Shearer G.M. Mother-to-infant transmission of HIV type 1: Role of major histocompatibility antigen differences. AIDS Res. Hum. Retroviruses. 12:1996;1397-1400.
36. Spruth M., Stoiber H., Kacani L., et al. Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients. AIDS Res. Hum. Retroviruses. 15:1999;533-543.
37. MacDonald K.S., Embree J., Njenga S., et al. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type I transmission. J. Infect. Dis. 177:1998;551-556.
38. Plummer F.A., Fowke K., Nagelkerke N.J.D., et al. Evidence of resistance to HIV among continuously exposed prostitutes in Nairobi, Kenya. IXth International Conference on AIDS, Berlin. 1993.
39. Pinto L.A., Sharpe S., Cohen D.I., Shearer G.M. Alloantigen-stimulated anti-HIV activity. Blood. 92:1998;3346-3354.
40. Wang Y., Tao L., Mitchell E., et al. Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women. Nat. Med. 5:1999;1004-1009.
41. Polyanskaya N., Sharpe S., Cook N., et al. Anti-major histocompatiblity complex antibody responses to simian B cells do not protect macaqeus against SIVmac infection. AIDS Res. Hum. Retroviruses. 12:1997;923-931.
42. Luscher M.A., Dela Cruz C.S., MacDonald K.S., Barber B.H. Concerning the anti-major histocompatibility complex approach to HIV-1 vaccine design. AIDS Res. Hum. Retroviruses. 14:1998;541-544.
43. Novotny V.M., van Doorn R., Witvliet M.D., et al. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood. 85:1995;1736-1741.
44. Goldberg J.S., Haynes M.K., Cowchock F.S., et al. Alloantibody responses to antigens recognized by rabbit antitrophoblast antisera in trophoblast and mononuclear cell (MNC) membranes by primary aborting women before and after paternal leukocyte immunization. Am. J. Reprod. Immunol. 33:1995;21-30.
45. Robinson H.L., Torres C.A. DNA vaccines. Semin. Immunol. 9:1997;271-283.
46. Calarota S., Bratt G., Nordlund S., et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. The Lancet. 351:1998;1320-1325.
47. Wang R., Doolan D.L., Le T.P., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 282:1998;476-480.
48. MacGregor R.R., Boyer J.D., Ugen K.E., et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis. 178:1998;92.
49. Yasutomi Y., Robinson H.L., Lu S., et al. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus macaques. J. Virol. 70:1996;678-681.
50. Lu S., Arthos J., Montefiori D.C., et al. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 70:1996;3978-3991.
51. Boyer J.D., Ugen K.E., Wang B., et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med. 3:1997;526-532.
52. Lodmell D.L., Ray N.B., Parnell M.J., et al. DNA immunization protects nonhuman primates against rabies virus. Nat. Med. 4:1998;949-952.
53. Robinson H.L., Montefiori D.C., Johnson R.P., et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 5:1999;526-534.
54. Kent S.J., Zhao A., Best S.J., et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72:1998;10180-10188.
55. Hanke T., Neumann V.C., Blanchard T.J., et al. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine. 17:1999;589-596.
56. Okuda K., Xin K.O., Tsuji T., et al. DNA vaccination followed by macromolecular multicomponent peptide vaccination against HIV-1 induces strong antigen-specific immunity. Vaccine. 15:1997;1049-1056.
57. Fuller D.H., Murphey Corb M., Baranett S., et al. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine. 15:1997;924-926.
58. Gleich L.L., Gluckman J.L., Armstrong S., et al. Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial. Arch. Otolaryngol. Head Neck Surg. 124:1998;1097-1104.
59. Stopeck A.T., Hersh E.M., Akporiaye E.T., et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J. Clin. Oncology. 15:1997;341-349.
60. Rubin J., Galanis E., Pitot H.C., et al. Phase I study of immunotherapy of hepatic metastases of colorectal by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther. 4:1997;419-425.
61. Nabel G.J., Gordon D., Bishop D.K., et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl. Acad. Sci. USA. 93:1996;15388-15393.
62. Gulukota K., DeLisi C. HLA allele selection for designing peptide vaccines. Genet. Anal1. 3:1996;81-86.
63. Mellors J.W., Rinaldo C.R. Jr, Gupta P., et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1996;1167-1170.